Ranolazine

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

56 API Suppliers, 28 USDMF, 17 EU WC, 1 KDMF, 22 NDC API, 38 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

INTERMEDIATES

18 Intermediates Suppliers

18 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

109 FDF Dossiers, 54 FDA Orange Book, 28 Europe, 2 Canada, 3 South Africa, 22 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET, EXTENDED RELEASE;ORAL - 1GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, GRANULES, EXTENDED RELEASE;ORAL - 1GM, GRANULES, EXTENDED RELEASE;ORAL - 500MG

RELATED EXCIPIENT COMPANIES

1 Evonik, 1 SPI Pharma, 2 DKSH, 1 Jai Radhe Sales, 2 Faran Shimi Pharmaceutical, 8 Gangwal Healthcare, 4 Nanjing Well Pharmaceutical, 1 ACG Worldwide, 2 Actylis, 1 Aeon Procare, 1 Alcedo Pharmachem, 3 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 6 BASF, 1 Clariant, 13 Corel Pharma Chem, 4 DFE Pharma, 10 Gangwal Chemicals, 11 Ideal Cures Pvt Ltd, 31 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 10 Microlex e.U, 1 Nanjing Bold Chemical, 2 Novo Excipients, 1 Pharmatrans-Sanaq, 2 Pluviaendo, 2 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 9 Roquette, 12 Seppic, 3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 10 Sigachi Industries, 2 The Dow Chemical Company, 1 Valens Pharmachem, 2 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

62 Coating Systems & Additives, 44 Fillers, Diluents & Binders, 32 Controlled & Modified Release, 20 Direct Compression, 14 Thickeners and Stabilizers, 14 Solubilizers, 13 Lubricants & Glidants, 12 Film Formers & Plasticizers, 12 Co-Processed Excipients, 10 Granulation, 9 Parenteral, 7 Topical, 7 Disintegrants & Superdisintegrants, 6 Taste Masking, 5 Emulsifying Agents, 5 Empty Capsules, 5 API Stability Enhancers, 4 Rheology Modifiers, 4 Vegetarian Capsules, 4 Coloring Agents, 3 Chewable & Orodispersible Aids, 3 Surfactant & Foaming Agents

DIGITAL CONTENT

2 DATA COMPILATION #PharmaFlow, 25 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 25 Finished Drug Prices, 8 Annual Reports

MARKET PLACE

17 APIs, 2 FDF Dossiers

PATENTS & EXCLUSIVITIES

3 US Patents

3 US Patents

REF. STANDARDS & IMPURITIES

4 USP, 9 Others

ANALYTICAL

2 BioAnalytical Methods

2 BioAnalytical Methods

$ Xls

Filters

Xls

USFDA APPLICATION NUMBER - 216018 / DOSAGE - GRANULES, EXTENDED RELEASE;ORAL - 500MG

Ingredient Name	Basis of Strength	Strength
Active Ingredient/Active Moiety
RANOLAZINE(UNII: A6IEZ5M406) (RANOLAZINE - UNII:A6IEZ5M406)	RANOLAZINE	500mg \| 1000mg

Inactive Ingredients

Ingredient Name	SUN PHARMACEUTICAL INDUSTRIES, INC.
DIBUTYL SEBACATE(4W5IH7FLNY)
DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER(905HNO1SIH)
ETHYLCELLULOSE, UNSPECIFIED(7Z8S9VYZ4B)
HYPROMELLOSE, UNSPECIFIED(3NXW29V3WO)
MAGNESIUM STEARATE(70097M6I30)
METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A(NX76LV5T8J)
MICROCRYSTALLINE CELLULOSE(OP1R32D61U)
TALC(7SEV7J4R1U)

Drug Product Composition: Ranolazine

Ranolazine

Ranolazine

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

56 API Suppliers

28 USDMF

17 EU WC

1 KDMF

22 NDC API

38 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

1 Drugs in Development

INTERMEDIATES

18 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

109 FDF Dossiers

54 FDA Orange Book

28 Europe

2 Canada

3 South Africa

22 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET, EXTENDED RELEASE;ORAL - 1GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, EXTENDED RELEASE;ORAL - 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

GRANULES, EXTENDED RELEASE;ORAL - 1GM

GRANULES, EXTENDED RELEASE;ORAL - 500MG

RELATED EXCIPIENT COMPANIES

1 Evonik

1 SPI Pharma

2 DKSH

1 Jai Radhe Sales

2 Faran Shimi Pharmaceutical

8 Gangwal Healthcare

4 Nanjing Well Pharmaceutical

1 ACG Worldwide

2 Actylis

1 Aeon Procare

1 Alcedo Pharmachem

3 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

6 BASF

1 Clariant

13 Corel Pharma Chem

4 DFE Pharma

10 Gangwal Chemicals

11 Ideal Cures Pvt Ltd

31 Kerry

3 Kima Chemical

6 Lonza Capsugel

10 Microlex e.U

1 Nanjing Bold Chemical

2 Novo Excipients

1 Pharmatrans-Sanaq

2 Pluviaendo

2 Prachin Chemical

1 Qianhao Chemical (Hebei) Co., Ltd

1 Qualicaps

9 Roquette

12 Seppic

3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

10 Sigachi Industries

2 The Dow Chemical Company

1 Valens Pharmachem

2 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

62 Coating Systems & Additives

44 Fillers, Diluents & Binders

32 Controlled & Modified Release

20 Direct Compression

14 Thickeners and Stabilizers

14 Solubilizers

13 Lubricants & Glidants

12 Film Formers & Plasticizers

12 Co-Processed Excipients

10 Granulation

9 Parenteral

TABLET, EXTENDED RELEASE;ORAL - 1GM Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, EXTENDED RELEASE;ORAL - 500MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons